Combretastatin A-4 phosphate: Vascular disrupting agent oncolytic treatment of age-related macular degeneration

Drugs of the Future

Volumn 32, Issue 12, 2007, Pages 1025-1032

  Patterson, Daniel M ^a   Rustin, Gordon J S ^a   Serradell, N ^b   Rosa, E ^b   Bolos J ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ARSENIC TRIOXIDE; AURISTATIN PE; AZD 6126; BEVACIZUMAB; CARBOPLATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; DENIBULIN; MN 029; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NPI 2358; PACLITAXEL; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SOBLIDOTIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; ZYBRESTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA; BONE MARROW TOXICITY; BRADYCARDIA; CARDIOTOXICITY; CLINICAL TRIAL; DIPLOPIA; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; ESOPHAGUS CANCER; GASTROINTESTINAL DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE ISCHEMIA; LUNG SMALL CELL CANCER; MONOTHERAPY; MOTOR NEUROPATHY; NEOVASCULARIZATION (PATHOLOGY); NEUROLOGIC DISEASE; NONHUMAN; OVARY CANCER; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; SENSORIMOTOR NEUROPATHY; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA; THYROID CANCER; TUMOR PAIN; TUMOR VASCULARIZATION;

EID: 41549158330     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.12.1158960     Document Type: Article

References (62)

1. Pettit, G.R., Temple, C. Jr., Narayanan, V.L. et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995, 10(4): 299-309.
2. Pettit, G.R. (Arizona State University). Combretastatin A-4 prodrug. US 5561122.
3. Pettit, G.R., Rhodes, M.R. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des 1998, 13(3): 183-91.
4. Pettit, G.R., Rhodes, M.R. (Arizona State University). Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof. CA 2314238, EP 1045853, US 7018987, WO 9935150.
5. Gale, J., Haider, R., Hoare, J., Seyedi, F. (OxiGene, Inc.). Efficient method of synthesizing combretastatin A-4 prodrugs. US 2002119951, WO 0206279.
6. Griffin, R.J., Quarterman, C.P., Rathbone, D.L., Slack, J.A. (Aston Molecules Ltd.). Substd. diphenylethylenes and analogues of derivs. thereof. WO 9216486.
7. Gill, G.S., Grobelny, D., Flynn, B. A practical method for phosphorylation of combretastatin A-4 with phosphorus oxychloride. Org Prep Proc Int 2006, 38(6): 604-8.
8. Walshe, W.W. (Ed.). The Anatomy, Physiology, Pathology and Treatment of Cancer. Ticknor and Company, Boston, 1844.
9. Woglom, W.H. A critique of tumour resistance. J Cancer Res 1923, 7: 283-311.
10. Boyland, E., Boyland, M.E. Studies in tissue metabolism: The action of colchicine and B. typhosus extract. Biochem J 1937, 31(3): 454-60.
11. Boyland, E., Boyland, M.E. Studies in tissue metabolism: The action of colchicine on transplanted, induced and spontaneous mouse tumours. Biochem J 1940, 34(3): 280-4.
12. Ludford, R.J. Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst 1945, 6: 89-101.
13. Ludford, R.J. Factors determining the action of colchicine on tumour growth. Br J Cancer 1948, 2: 75-86.
14. Seed, L., Slaughter, D.P., Limarzi, L.R. Effect of colchicine on human carcinoma. Surgery 1940, 7: 696-709.
15. Leiter, J., Downing, V., Hartwell, J.L., Shear, M.J. Damage induced in sarcoma 37 with podophyllin, podophyllotoxin alpha-peltatin, beta-peltatin, and quercetin. J Natl Cancer Inst 1950, 10(6): 1273-93.
16. Denekamp, J., Hobson, B. Endothelial-cell proliferation in experimental tumours. Br J Cancer 1982, 46(5): 711-20.
17. Denekamp, J., Hill, S.A., Hobson, B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 1983, 19(2): 271-5.
18. Dark, G.G., Hill, S.A., Prise, V.E., Tozer, G.M., Pettit, G.R., Chaplin, D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 1997, 57(10): 1829-34.
19. Pettit, G.R., Cragg, G.M., Herald, D.L., Schmidt, J.M., Lohavanijaya, P. Isolation and structure of combretastatin. Can J Chem 1982, 60: 1374-6.
20. Patterson, D.M., Rustin, G.J. Vascular damaging agents. Clin Oncol (R Coll Radiol) 2007, 19(6): 443-56.
21. Rustin, G.J., Galbraith, S.M., Anderson, H. et al. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 2003, 21(15): 2815-22.
22. Lin, C.M., Singh, S.B., Chu, P.S., Dempcy, R.O., Schmidt, J.M., Pettit, G.R., Hamel, E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Mol Pharmacol 1988, 34(2): 200-8.
23. Lin, C.M., Ho, H.H., Pettit, G.R., Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28(17): 6984-91.
24. Galbraith, S.M., Chaplin, D.J., Lee, F., Stratford, M.R., Locke, R.J., Vojnovic, B., Tozer, G.M. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001, 21(1A): 93-102.
25. el-Zayat, A.A., Degen, D., Drabek, S., Clark, G.M., Pettit, G.R., Von Hoff, D.D. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 1993, 4(1): 19-25.
26. Grosios, K., Holwell, S.E., McGown, A.T., Pettit, G.R., Bibby, M.C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999, 81(8): 1318-27.
27. Iyer, S., Chaplin, D.J., Rosenthal, D.S., Boulares, A.H., Li, L.Y., Smulson, M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998, 58(20): 4510-4.
28. Chaplin, D.J., Pettit, G.R., Hill, S.A. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 1999. 19(1A): 189-95.
29. Beauregard, D.A., Thelwall, P.E., Chaplin, D.J., Hill, S.A., Adams, G.E., Brindle, K.M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998, 77: 1761-7.
30. Galbraith, S.M., Maxwell, R.J., Lodge, M.A. et al. Combretastatin A4 phosphate has tumour anti-vascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21(15): 2831-42.
31. Maxwell, R., Wilson, J., Prise, V.E., Vojnovic, B., Rustin, G.J., Lodge, M.A., Tozer, G.M. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002, 15(2): 89-98.
32. Tozer, G.M., Prise, V.E., Wilson, J. et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 2001, 61(17): 6413-22.
33. Tozer, G.M., Prise, V.E., Wilson, J. et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999, 59(7): 1626-34.
34. Horsman, M.R., Murata, R., Breidahl, T. et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000, 476: 311-23.
35. Nelkin, B.D., Ball, D.W. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001, 8(1): 157-60.
36. Murata, R., Siemann, D.W., Overgaard, J., Horsman, M.R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001, 60(2): 155-61.
37. Snaked, Y., Ciarrocchi, A., Francoet, M. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006. 313(5794): 1785-7.
38. Griggs, J., Hesketh, R., Smith, G.A., Brindle, K.M., Metcalfe, J.C., Thomas, G.A., Williams, E.D. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 2001, 84(6): 832-5.
39. Griggs, J., Skepper, J.N., Smith, G.A., Brindle, K.M., Metcalfe, J.C., Hesketh, R. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 2002, 160(3): 1097-103.
40. Nambu, H., Nambu, R., Melia, M., Campochiaro, P.A. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44(8): 3650-5.
41. Stevenson, J.P., Rosen, M., Sun, W. et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003, 21(23): 4428-38.
42. Dowlati, A., Robertson, K., Cooney, M. et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62(12): 3408-16.
43. Bilenker, J.H., Flaherty, K.T., Rosen, M. et al. Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 2005, 11(4): 1527-33.
44. Anderson, H.L., Yap, J.T., Miller, M.P., Robbins, A., Jones, T., Price, P.M. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003, 21(15): 2823-30.
45. Cooney, M.M., Radivoyevitch, T., Dowlati, A. et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004, 10(1, Pt. 1): 96-100.
46. Rustin, G.J.S., Nathan, P.D., Boxall, J., Saunders, L., Ganeson, T.S., Wang, D., Gaya, A. A dose escalation study combining combretastatin A-4 phosphate (CA4P) with carboplatin or paclitaxel in patients with advanced cancer. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst A12. 47. Safety study of increasing doses of combretastatin in combination with bevacizumab (Avastin) in patients with advanced solid tumors (NCT00395434). ClinicalTrials.gov Web site, November 27, 2007.
47. Study of combretastatin and paclitaxel/carboplatin in the treatment of anaplastic thyroid cancer (NCT00507429). ClinicalTrials.gov Web site, Novermber 27, 2007.
48. Jameson, M.B., Thompson, P.I., Baguley, B.C. et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003, 88(12): 1844-50.
49. Rustin, G.J., Bradley, C., Galbraith, S. et al. 5,6- Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer 2003, 88(8): 1160-7.
50. McKeage, M., AS1404-201 Study Group Investigators. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 7102.
51. Gabra, H., AS1404-202 Study Group Investigators. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 5032.
52. Rustin, G.J.S., Nathan, P.D., Boxall, J., Saunders, L., Ganesan, T.S., Shreeves, G.E. A phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3103.
53. Beerepoot, L.V., Radema, S.A., Witteveen, E.O., Thomas, T., Wheeler, C., Kempin, S., Voest, E.E. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006, 24(10): 1491-8.
54. Tolcher, A.W., Forero, L., Celio, P. et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 834.
55. Fox, E., Maris, J.M., Widemann, B.C. et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006, 12(16): 4882-7.
56. Ricart, A.D., Cooney, M., Sarantopoulos, J. et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 3096.
57. Patterson, D.M., Ross, P., Koetz, B. et al. Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18. Suppl.): Abst 14146.
58. Tamura, K., Nakagawa, K., Kurata, T. et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 2007, 60(2): 285-93.
59. Patel, S., Keohan, M.L., Saif, M.W. et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006, 107(12): 2881-7.
60. Schoffski, P., Thate, B., Beutel, G. et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004, 15(4): 671-9.
61. Spear, M.A., LoRusso, P., Tolcher, A.W. et al. A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18. Suppl.): Abst 14097.
62. Soignet, S.L., Maslak, P., Wang, Z.G. et al. Complete remission after treatment of acute promyelocyte leukemia with arsenic trioxide. N Engl J Med 1998, 339(19): 1341-8.